Toxicity
A summary of the toxicities associated with this protocol are included in the table below. The most clinically significant toxicities for this treatment are myelosuppression and gastrointestinal toxicities.
Grade 3/4 toxicity |
Study |
Incidence of event
(%) |
Neutropenia |
Freyer et al. 2003r
(n=64) |
39.1 |
Leucopenia |
Freyer et al. 2003r
(n=64) |
28.1 |
Anaemia |
Freyer et al. 2003r
(n=64) |
6.3 |
Thrombocytopenia |
Mansour et al. 2010r
(n=26) |
6.4 |
Infection |
Mansour et al. 2010r
(n=26) |
6.4 |
Nausea/Vomiting |
Amadori et al. 2001r
(n=72) |
31.8* |
Diarrhoea |
Amadori et al. 2001r
(n=72) |
8.5 |
Constipation |
Freyer et al. 2003r
(n=64) |
1.6 |
Stomatitis |
Freyer et al. 2003r
(n=64) |
3.1 |
Neuropathy |
Freyer et al. 2003r
(n=64) |
1.6 |
Fatigue |
Palomo et al. 2012r
(n=116) |
3 |
Alopecia
(Grade 2) |
Palomo et al. 2012r
(n=116) |
2 |
* no primary prophylactic antiemetics administered
A quality of life questionnaire performed in the study by Freyer et al, revealed no significant alteration between baseline, week 8 and 16, in global quality of life.r
Caregivers described these oral regimens as convenient (81%), well tolerated (84%), and with good compliance by patients (76%).r